Modern Management of Chronic Venous Insufficiency  by Bradbury, Andrew W.




In Caucasians, the life-time risk of developing varicose veins
(VVs) is 30% to 50%; for venous hypertensive skin changes of
chronic venous insufficiency (CVI), it is 5% to 10%; and for
chronic venous ulceration (CVU), it is around 1%.1–3 In most
European countries and in North America, the treatment of
CVI consumes approximately 2% of total health care spending4
and is a major cause of lost economic productivity through
sickness and absence from work. Similar data for Asian
countries appear unavailable, at least in the English-language
literature. However, there is no reason to believe that other
ethnic groups and races are immune from a disease that
appears to be a direct consequence of Homo sapiens’ bipedal
posture.
Given that CVI is generally accepted to be a leading
worldwide cause of medical and socio-economic morbidity,
one would expect health care purchasers to place a high priority
on its treatment, those treatments to be evidence-based and
clinically- and cost-effective and, where that is not the case,
funding bodies to be keen to fund clinical and basic science
research.5 In the UK, where VV surgery is the commonest cause
of litigation against general and vascular surgeons,6–8 where
those in charge of the National Health Service (NHS)
purse-strings constantly try to ration the treatment of CVI,
and where venous disease receives a low priority in the allocation
of research monies, nothing could be further from the truth.
No doubt, similar constraints face practitioners in other
countries. How has this state of affairs come to pass? There are
two main reasons: firstly, until recently, we have been unable to
demonstrate that surgery for CVI ameliorates the physical
symptoms (as opposed to the cosmetic concerns) associated
with VVs9,10 or confers additional benefit over the “best medical
therapy” in terms of preventing, healing and reducing the
recurrence of CVU. Secondly, many patients with lower limb
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venous disease find the current levels of morbidity and long-
term failure11 associated with conventional venous surgery
unacceptable. The first has led researchers to devise and
construct trials that will provide “level 1” evidence (i.e. evidence
based on clinical and health economic data derived from
randomized controlled trials) of clinical and cost-efficacy; the
second has led doctors and patients alike to search for alter-
native, minimally invasive therapies to replace conventional
surgery.12
Quest for the evidence base
Until recently, the evidence base for what we were taught at
medical school about treating lower limb venous disease was
virtually non-existent.13 However, in recent years, there have
been major steps forward in our understanding of the
pathophysiology14,15 of the disease and its diagnosis and
treatment.16 With regard to long saphenous vein (LSV) VV
surgery, we now have ample level 1 evidence to show that the
most important component of the operation is stripping of
the LSV in the thigh.17–20 This paradigm shift has allowed for
the rational introduction of new, minimally invasive
techniques.21 We also know that superficial venous surgery,
whether performed for uncomplicated VVs or the more severe
dermatological manifestations of CVI, is associated with a
significant improvement in health-related quality of
life.18–22 Very recently, the ESCHAR study, a randomized
controlled trial (RCT),23 confirmed the findings of uncon-
trolled studies24 that the addition of saphenous surgery to
compression therapy significantly reduces recurrence of CVU.
Sub-fascial endoscopic perforator surgery
For a while, great hopes and expectations accompanied the
advent of sub-fascial endoscopic perforating surgery (SEPS).25
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Like many practitioners, the author performed a large number
of procedures, believing intuitively that the interruption of
high-pressure venous flow from the deep compartment of the
calf to the skin of the gaiter area would be beneficial.26 However,
while the procedure can certainly be performed expeditiously
with a minimum of morbidity,27 it is now clear that many
perforators regain competence once saphenous reflux has
been abolished.28 Furthermore, although the North American
SEPS registry reported encouraging ulcer healing rates, longer-
term follow-up to 2 years revealed disappointing recurrence
rates similar to those obtained by compression therapy alone.
This was especially so in patients with deep venous reflux,
particularly where this was believed to be post-thrombotic in
aetiology.29,30
While the author believes that the procedure still has a role
in the management of CVI, its benefits over compression
and/or saphenous surgery alone may be small and restricted to
certain subgroups of patients. There are no short cuts, and the
surgical community must be prepared to work together to
complete scientifically credible RCTs to tease out the answers
to these difficult questions. The author is a co-investigator in
such an ongoing, UK-based, Medical Research Council-funded
RCT, in which the results will hopefully be reported in 2005 or
2006. Other trials are also underway in the UK and elsewhere
and have yet to report their findings.
Quest for new treatments
In an attempt to improve outcomes and minimize morbidity,
a number of novel, minimally invasive alternative therapies
have been developed and promoted in recent years.
Radio-frequency ablation
Perhaps the best known and documented of the new techniques
is radio-frequency (RF) ablation of the LSV in the thigh (Closure
Technique, VNUS Medical Technologies Inc., Sunnyvale,
CA, USA, www.vnus.com). An RF catheter is introduced
percutaneously into the LSV, advanced to the sapheno-femoral
junction, heated, and then withdrawn slowly under duplex
ultrasound guidance. A recently published registry of 286
patients from 30 different sites in North America and Europe
has indicated that the VNUS procedure leads to LSV occlusion
in almost 90% of patients 24 months post-procedure.31 A small
RCT of 28 patients has shown VNUS to be associated with less
post-procedure morbidity and an earlier return to full physical
function. Although the initial financial outlay for VNUS is
greater than for conventional surgery, the authors argue that
the quicker recovery time will translate into an overall “cost
savings for society”.32 Whether this turns out to be the case
remains to be seen and will, of course, depend on the particular
health reimbursement system at work in each individual
country.
Endovenous laser therapy
In principle, endovenous laser therapy (EVLT) (Diomed Ltd.,
Cambridge, UK, www.evlt.com) is quite similar to VNUS
Closure, except that the LSV is obliterated using a laser.
Although there are fewer data currently available in the
literature, short-term results in small numbers of patients
treated in uncontrolled studies of EVLT suggest that the
incidence of vein obliteration is similar to that experienced
after VNUS Closure.33
Powered phlebectomy (TriVex)
Smith and Nephew (Smith & Nephew Plc., London, UK,
www.smith-nephew.com/businesses/E_trivex.html) have
developed this device, which morcelates and removes varices,
so replacing the need for multiple stab avulsions or
sclerotherapy following LSV obliteration.34,35 The advantages
are fewer skin incisions and greater speed, especially when
performing bilateral surgery. The latter may extend the role of
day surgery in such patients.
Foam sclerotherapy
The idea that sclerosants can be mixed with air and other
gases to increase their efficacy in not new.36 However, it was
not until Cabrera published his results with “foam” that the
concept was popularized.36 The main advantage of foam over
liquid sclerosant is that it completely displaces all the blood
from the vein being treated, which then almost immediately
goes into intense spasm. This reduces the risk of
thrombophlebitis. Even very large trunk varices can be treated
with quite small volumes of weak sclerosant. Cabrera patented
his discovery and Provensis Ltd., a wholly owned subsidiary of
the British Biotechnology Group Plc. (www.btgplc.com), was
created to develop Cabrera’s intellectual property in relation
to the foam. The resultant product, Varisolve, is comprised of
1% polidocanol and a mixture of physiological gases. The
foam is introduced into the LSV, or short saphenous vein, via
a cannula that is placed percutaneously under duplex
ultrasound control, under local anaesthesia. As the foam is
highly echogenic, it can be delivered in an extremely controlled
and precise way to fill the whole main trunk up to, but not
beyond, the sapheno-femoral or sapheno-popliteal junctions.
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As Varisolve is highly surface active, it also quickly fills and
obliterates all the distal varices; experience suggests that most
patients’ VVs are eradicated following a single treatment.
Trials comparing Varisolve to surgery and other forms of
sclerotherapy are currently underway in Europe, including
the UK, in order to gain FDA approval and European licences.
Will these new techniques pose a serious “threat” to
conventional surgery? In countries like the UK where most
surgery for CVI is paid for by the public sector, these new and
often more expensive and complex procedures are unlikely to
have a dramatic impact on overall practice. However, in
countries where private sector health care is predominant, and
where patient preference and convenience are paramount and
costs are less important, these new techniques and their
proponents are more likely to prosper. However, training in
patient selection as well as in the performance of the procedure
itself is going to be crucial to optimizing results. To their
credit, all of the companies involved have embarked upon such
training programmes, not least because they realize that
complications and bad results will dent confidence in their
product and limit the return on their R&D investment.
Conclusions
There has never been a more interesting or rewarding time
to be involved in the treatment of CVI. Our improved
understanding of the macro- and microvascular abnormalities
that lead to its symptoms and signs has enabled us to refine
existing treatments and develop new techniques that are likely
to provide our patients with a safer, more pleasant treatment
experience and better long-term outcomes. However, with
that comes a responsibility to ensure that the management of
our patients is evidence-based, that we audit and report our
results wholly and truthfully (whether they are good or bad),
and that we maintain the highest scientific standards when
conducting clinical and basic science research into venous
disease.37
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